The results of the Cabopoint study presented at GU ASCO 2023 indicated that cabozantinib could be a promising second-line treatment option for patients with renal cell carcinoma who have experienced disease progression after prior treatment with ipilimumab plus nivolumab (Cohort A) or immunotherapy plus TKI (Cohort B). In Cohort A, the response rate was 31.7% after treatment with cabozantinib following ipi/nivo, while the response rate was 25% after immunotherapy/TKI.
These findings suggest that cabozantinib may be an active option for some patients in the second-line setting. It is important to note that Cabopoint is a phase 2 study and further research is needed to confirm the efficacy and safety of this approach.
The interim findings from the Cabopoint study suggest that it may have efficacy as a second-line treatment option for the overall population, as well as across various subgroups. The final analysis is expected to be completed in September 2023.
